A new paradigm of quality of care in rheumatoid arthritis: how our new therapeutics have changed the game.

Demonstrating the effectiveness of expensive new rheumatoid arthritis (RA) therapeutics is imperative to determine whether the quality of care has improved with the introduction of these agents. Our current RA quality measures are primarily process based, but they must become outcomes based to better demonstrate quality. New RA quality measures must be multidimensional, accounting for all of the important outcomes in RA: radiographic, functional status, and disease activity. To fully understand the potential benefits of new therapeutics in RA, outcome measures must be integrated with routine practice.
AuthorsSonali P Desai, Daniel H Solomon
JournalArthritis research & therapy (Arthritis Res Ther) Vol. 15 Issue 5 Pg. 121 ( 2013) ISSN: 1478-6362 [Electronic] England
PMID24164739 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Antirheumatic Agents
  • Antirheumatic Agents (therapeutic use)
  • Arthritis, Rheumatoid (drug therapy)
  • Humans
  • Outcome Assessment (Health Care) (methods, standards)
  • Quality Assurance, Health Care (standards)
  • Quality Indicators, Health Care (standards)
  • Quality of Life

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: